A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients ...
Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) ...
Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host ...
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
The Brighterside of News on MSN
Study finds low-dose CAR T therapy can drive complete cancer remission
A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...
Cellenkos receives US FDA clearance to initiate phase 1b/2a trial of CK0802 in steroid-refractory graft-versus-host disease: Houston Thursday, May 7, 2026, 18:00 Hrs [IST] Cellenk ...
Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...
Please provide your email address to receive an email when new articles are posted on . Over 65% of patient-reported treatment responses agreed with clinicians’ evaluations, whereas 34.4% did not.
A reduced-intensity bone marrow transplant regimen developed by Johns Hopkins physicians provides durable engraftment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results